Scotiabank Begins Coverage of Regeneron with a Sector Perform Rating
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2025
0mins
Should l Buy REGN?
- Analyst Coverage: Scotiabank analyst Louise Chen has started coverage of Regeneron Pharmaceuticals.
- Rating and Price Target: The stock has been given a Sector Perform rating with a price target set at $650.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 749.410
Low
637.00
Averages
808.50
High
1057
Current: 749.410
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Opportunities in Biotech Stocks
- Moderna's Innovative Potential: Moderna's mRNA vaccine platform allows for faster vaccine design compared to traditional methods, which could drive long-term returns, especially given the increased uncertainty in the COVID-19 vaccine market, where the company's deep pipeline and innovative technology may yield significant investment returns.
- Diverse Pipeline Products: Moderna is developing a vaccine for norovirus and a personalized cancer vaccine, mRNA-4157, which has shown significant potential in mid-stage trials to reduce recurrence and death risk in melanoma patients, further enhancing its market competitiveness.
- Regeneron's Market Leadership: Regeneron's Dupixent is a top-selling drug globally, particularly after gaining important label expansions for COPD treatment, expected to continue driving sales growth, while its high-dose Eylea offers a more patient-friendly dosing regimen, attracting patients despite biosimilar competition.
- Diversified Product Pipeline: Regeneron is developing products across various therapeutic areas, including gene therapy for genetic deafness and anti-obesity medications, which, if approved, could boost revenue and earnings, while its dividend and share buyback program demonstrate a commitment to returning capital to shareholders.
See More
NIMBLE Trial Shows Significant Efficacy of Cemdisiran for gMG
- Significant Efficacy: The NIMBLE trial demonstrated that patients treated with cemdisiran showed a 4.5-point improvement in the Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score at week 24 compared to a 2.2-point improvement in the placebo group, indicating cemdisiran's potential best-in-class efficacy in improving daily functions for gMG patients.
- Rapid Improvement: Among patients receiving cemdisiran, 76.6% achieved a ≥3-point improvement, compared to only 44.1% in the placebo group, highlighting cemdisiran's ability to significantly enhance patient quality of life in a short timeframe, addressing the urgent need for effective treatments.
- Good Safety Profile: In the NIMBLE trial, 69.2% of cemdisiran patients experienced treatment-emergent adverse events (AEs), most of which were mild to moderate, and there were no treatment discontinuations due to AEs through week 24, demonstrating cemdisiran's favorable tolerability.
- Regulatory Application Submitted: Regeneron submitted a regulatory application for cemdisiran to U.S. authorities in Q1 2026, and if approved, it will become the first siRNA therapy for gMG, marking a significant advancement in this therapeutic area.
See More
Sanofi's COVID-19 Vaccine Shows Better Tolerability than Moderna's
- Tolerability Comparison: Sanofi's Nuvaxovid vaccine demonstrated a significantly better tolerability profile in a head-to-head study against Moderna's mNEXSPIKE, with less than 10% of Nuvaxovid recipients experiencing systemic side effects compared to 20% for mNEXSPIKE.
- Side Effect Rates: The COMPARE study revealed that 83.6% of Nuvaxovid recipients experienced systemic reactions, while 91.6% of mNEXSPIKE recipients did, highlighting Nuvaxovid's advantage in side effects, which may enhance vaccine confidence.
- Patient Feedback: Participants reported less disruption to work, school, and daily activities after receiving Nuvaxovid, with nearly twice as many Nuvaxovid recipients indicating they would choose the same vaccine again, underscoring the impact of tolerability on vaccination behavior.
- Market Reaction: As of April 17, Sanofi's stock price stood at $48.06, reflecting a 0.71% increase, and further rose to $48.25 in after-hours trading, indicating a positive market response to the vaccine study results.
See More
Teva's FDA Approval of Long-Acting Drug Could Be Major Catalyst
- New Drug Approval Outlook: Teva's New Drug Application for long-acting schizophrenia drug olanzapine has been accepted by the FDA, and if approved, it is expected to significantly enhance patient adherence, driving sales growth and becoming the company's most meaningful catalyst.
- Specialty Drug Sales Surge: Teva's Austedo generated $2.26 billion in sales in 2025, marking a 34% year-over-year increase, with expectations to reach between $2.4 billion and $2.55 billion in 2026, showcasing strong momentum in the specialty drug sector.
- Biosimilar Market Expansion: Teva plans to launch six new biosimilars in 2026 and 2027, potentially competing with Amgen and Johnson & Johnson, which will further solidify its position as the second-largest player in the biosimilar market.
- Investor Confidence Boost: Analysts are optimistic about Teva's future, with 12 out of 15 analysts rating the stock as a
See More
Teva Pharmaceutical Shares Surge 130% with Optimistic Outlook
- FDA Approval Catalyst: Teva's long-acting olanzapine injectable suspension NDA has been accepted by the FDA, with a decision expected later this year; approval could significantly enhance patient adherence, with combined annual sales with Uzedy projected to exceed $2 billion.
- Specialty Drug Sales Surge: Teva's specialty drug Austedo generated $2.26 billion in sales in 2025, a 34% year-over-year increase, with expectations for 2026 sales to rise between $2.4 billion and $2.55 billion, reflecting strong market demand and competitive positioning in the specialty drug sector.
- Biosimilar Expansion: Teva plans to launch six new biosimilars in 2026 and 2027, further solidifying its position as the second-largest player in the biosimilar market, with anticipated competition against giants like Amgen and Johnson & Johnson, driving future revenue growth.
- Market Risk Factors: Despite several catalysts propelling stock price growth, a market crash or significant pipeline issues could derail Teva's momentum; however, the company's pipeline is relatively de-risked, and with a forward P/E of only 11.7, it presents a compelling value investment opportunity.
See More
AbbVie Ventures into Weight Loss Market with Promising Drug
- Clinical Trial Results: AbbVie's March 9 announcement of ABBV-295's clinical trial results indicates that patients receiving weekly treatment lost an average of 7.75% to 9.79% of their weight over 12 weeks, while those on biweekly or monthly regimens lost between 7.86% and 9.73% over 13 weeks, suggesting strong potential for the drug in the weight loss market.
- Competitive Market Pressure: Despite the promising initial data for ABBV-295, AbbVie faces intense competition in the weight loss market from companies like Eli Lilly, which have several late-stage obesity drugs, indicating that the market will become increasingly crowded before AbbVie can launch its product.
- Core Business Stability: AbbVie's primary therapeutic area remains immunology, with projected sales for Skyrizi and Rinvoq exceeding $31 billion in 2023, significantly surpassing Humira's peak sales, demonstrating the company's robust performance and growth potential in this sector.
- Optimistic Pipeline Outlook: Even if ABBV-295 fails in clinical trials, AbbVie has a deep pipeline of investigational products, including the ongoing ABBV-383 cancer treatment, which is expected to provide significant support for the company's future financial performance and further solidify its leadership in the pharmaceutical industry.
See More
Investment Opportunities in Biotech Stocks
- Moderna's Innovative Potential: Moderna's mRNA vaccine platform allows for faster vaccine design compared to traditional methods, which could drive long-term returns, especially given the increased uncertainty in the COVID-19 vaccine market, where the company's deep pipeline and innovative technology may yield significant investment returns.
- Diverse Pipeline Products: Moderna is developing a vaccine for norovirus and a personalized cancer vaccine, mRNA-4157, which has shown significant potential in mid-stage trials to reduce recurrence and death risk in melanoma patients, further enhancing its market competitiveness.
- Regeneron's Market Leadership: Regeneron's Dupixent is a top-selling drug globally, particularly after gaining important label expansions for COPD treatment, expected to continue driving sales growth, while its high-dose Eylea offers a more patient-friendly dosing regimen, attracting patients despite biosimilar competition.
- Diversified Product Pipeline: Regeneron is developing products across various therapeutic areas, including gene therapy for genetic deafness and anti-obesity medications, which, if approved, could boost revenue and earnings, while its dividend and share buyback program demonstrate a commitment to returning capital to shareholders.
See More
NIMBLE Trial Shows Significant Efficacy of Cemdisiran for gMG
- Significant Efficacy: The NIMBLE trial demonstrated that patients treated with cemdisiran showed a 4.5-point improvement in the Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score at week 24 compared to a 2.2-point improvement in the placebo group, indicating cemdisiran's potential best-in-class efficacy in improving daily functions for gMG patients.
- Rapid Improvement: Among patients receiving cemdisiran, 76.6% achieved a ≥3-point improvement, compared to only 44.1% in the placebo group, highlighting cemdisiran's ability to significantly enhance patient quality of life in a short timeframe, addressing the urgent need for effective treatments.
- Good Safety Profile: In the NIMBLE trial, 69.2% of cemdisiran patients experienced treatment-emergent adverse events (AEs), most of which were mild to moderate, and there were no treatment discontinuations due to AEs through week 24, demonstrating cemdisiran's favorable tolerability.
- Regulatory Application Submitted: Regeneron submitted a regulatory application for cemdisiran to U.S. authorities in Q1 2026, and if approved, it will become the first siRNA therapy for gMG, marking a significant advancement in this therapeutic area.
See More
Sanofi's COVID-19 Vaccine Shows Better Tolerability than Moderna's
- Tolerability Comparison: Sanofi's Nuvaxovid vaccine demonstrated a significantly better tolerability profile in a head-to-head study against Moderna's mNEXSPIKE, with less than 10% of Nuvaxovid recipients experiencing systemic side effects compared to 20% for mNEXSPIKE.
- Side Effect Rates: The COMPARE study revealed that 83.6% of Nuvaxovid recipients experienced systemic reactions, while 91.6% of mNEXSPIKE recipients did, highlighting Nuvaxovid's advantage in side effects, which may enhance vaccine confidence.
- Patient Feedback: Participants reported less disruption to work, school, and daily activities after receiving Nuvaxovid, with nearly twice as many Nuvaxovid recipients indicating they would choose the same vaccine again, underscoring the impact of tolerability on vaccination behavior.
- Market Reaction: As of April 17, Sanofi's stock price stood at $48.06, reflecting a 0.71% increase, and further rose to $48.25 in after-hours trading, indicating a positive market response to the vaccine study results.
See More
Teva's FDA Approval of Long-Acting Drug Could Be Major Catalyst
- New Drug Approval Outlook: Teva's New Drug Application for long-acting schizophrenia drug olanzapine has been accepted by the FDA, and if approved, it is expected to significantly enhance patient adherence, driving sales growth and becoming the company's most meaningful catalyst.
- Specialty Drug Sales Surge: Teva's Austedo generated $2.26 billion in sales in 2025, marking a 34% year-over-year increase, with expectations to reach between $2.4 billion and $2.55 billion in 2026, showcasing strong momentum in the specialty drug sector.
- Biosimilar Market Expansion: Teva plans to launch six new biosimilars in 2026 and 2027, potentially competing with Amgen and Johnson & Johnson, which will further solidify its position as the second-largest player in the biosimilar market.
- Investor Confidence Boost: Analysts are optimistic about Teva's future, with 12 out of 15 analysts rating the stock as a
See More
Teva Pharmaceutical Shares Surge 130% with Optimistic Outlook
- FDA Approval Catalyst: Teva's long-acting olanzapine injectable suspension NDA has been accepted by the FDA, with a decision expected later this year; approval could significantly enhance patient adherence, with combined annual sales with Uzedy projected to exceed $2 billion.
- Specialty Drug Sales Surge: Teva's specialty drug Austedo generated $2.26 billion in sales in 2025, a 34% year-over-year increase, with expectations for 2026 sales to rise between $2.4 billion and $2.55 billion, reflecting strong market demand and competitive positioning in the specialty drug sector.
- Biosimilar Expansion: Teva plans to launch six new biosimilars in 2026 and 2027, further solidifying its position as the second-largest player in the biosimilar market, with anticipated competition against giants like Amgen and Johnson & Johnson, driving future revenue growth.
- Market Risk Factors: Despite several catalysts propelling stock price growth, a market crash or significant pipeline issues could derail Teva's momentum; however, the company's pipeline is relatively de-risked, and with a forward P/E of only 11.7, it presents a compelling value investment opportunity.
See More
AbbVie Ventures into Weight Loss Market with Promising Drug
- Clinical Trial Results: AbbVie's March 9 announcement of ABBV-295's clinical trial results indicates that patients receiving weekly treatment lost an average of 7.75% to 9.79% of their weight over 12 weeks, while those on biweekly or monthly regimens lost between 7.86% and 9.73% over 13 weeks, suggesting strong potential for the drug in the weight loss market.
- Competitive Market Pressure: Despite the promising initial data for ABBV-295, AbbVie faces intense competition in the weight loss market from companies like Eli Lilly, which have several late-stage obesity drugs, indicating that the market will become increasingly crowded before AbbVie can launch its product.
- Core Business Stability: AbbVie's primary therapeutic area remains immunology, with projected sales for Skyrizi and Rinvoq exceeding $31 billion in 2023, significantly surpassing Humira's peak sales, demonstrating the company's robust performance and growth potential in this sector.
- Optimistic Pipeline Outlook: Even if ABBV-295 fails in clinical trials, AbbVie has a deep pipeline of investigational products, including the ongoing ABBV-383 cancer treatment, which is expected to provide significant support for the company's future financial performance and further solidify its leadership in the pharmaceutical industry.
See More
